和黄医药创新出海领军企业迎来收获期,多项催化有望落地

西部证券
24 Jan

小分子出海领军企业,坚持国际化道路。和黄医药已有13种肿瘤候选药物正在临床试验阶段,三种药物(呋喹替尼、索凡替尼及赛沃替尼)已在中国内地获得批准上市,呋喹替尼亦已在美国、欧盟、日本、中国香港和澳门及全球另外6个国家获得批准。第四种候选药物他泽司他已于中国海南先行区、香港及澳门等地获批。索乐匹尼布国内递交NDA,即将成为第五款商业化产品。和黄医药重视国际化合作,呋喹替尼海外授权武田,赛沃替尼阿斯利康...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10